Fucoidan inhibits EGFR redistribution and potentiates sorafenib to overcome sorafenib-resistant hepatocellular carcinoma

Fucoidan inhibits EGFR redistribution and potentiates sorafenib to overcome sorafenib-resistant hepatocellular carcinoma

Hepatocellular carcinoma (HCC) is one of the leading causes of cancer-related deaths worldwide. Although sorafenib is a standard first-line molecule-targeted drug against advanced HCC, the drug resistance development and adverse side effects usually limit its efficacy. This study investigated the ef...

Full description

Bibliographic Details
Main Authors: Jialiang Luo, Lei Li, Zhengyumeng Zhu, Bo Chang, Fan Deng, Di Wang, Xiao Lu, Daming Zuo, Qingyun Chen, Jia Zhou
Format: Article
Language:English
Published: Elsevier 2022-10-01
Series:Biomedicine & Pharmacotherapy
Subjects:
Fucoidan
Sorafenib resistance
Hepatocellular carcinoma
EGFR
Online Access:http://www.sciencedirect.com/science/article/pii/S075333222200991X

Similar Items

Similar Items